Filter your results
- 3
- 3
- 3
- 1
- 2
- 3
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitorsOncotarget, 2017, 8 (62), pp.105103-105114. ⟨10.18632/oncotarget.21707⟩
Journal articles
hal-02543375v1
|
||
|
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patientsEuropean Respiratory Journal, 2017, 50 (5), ⟨10.1183/13993003.00050-2017⟩
Journal articles
inserm-01819272v1
|
||
|
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018European Journal of Cancer, 2023, 183, pp.38-48. ⟨10.1016/j.ejca.2023.01.014⟩
Journal articles
hal-04016683v1
|